Gilead Sciences, Inc. (NASDAQ:GILD) – Research analysts at Svb Leerink cut their Q2 2019 earnings estimates for shares of Gilead Sciences in a note issued to investors on Monday, July 15th. Svb Leerink analyst G. Porges now forecasts that the biopharmaceutical company will post earnings of $1.71 per share for the quarter, down from their prior estimate of $1.72. Svb Leerink also issued estimates for Gilead Sciences’ Q3 2019 earnings at $1.70 EPS, Q4 2019 earnings at $1.65 EPS, FY2019 earnings at $6.74 EPS and FY2021 earnings at $6.90 EPS.
Other analysts have also recently issued research reports about the company. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Monday. Evercore ISI restated a “buy” rating on shares of Gilead Sciences in a research note on Friday, May 17th. BMO Capital Markets set a $76.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research note on Monday. Raymond James set a $60.00 price objective on Banner and gave the company a “buy” rating in a research note on Friday, May 3rd. Finally, Zacks Investment Research cut Hersha Hospitality Trust from a “buy” rating to a “hold” rating in a research note on Thursday, May 2nd. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and seventeen have assigned a buy rating to the company. Gilead Sciences has an average rating of “Buy” and a consensus target price of $80.99.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.53 by $0.23. Gilead Sciences had a return on equity of 37.98% and a net margin of 26.40%. The company had revenue of $5.28 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter in the prior year, the business earned $1.48 earnings per share. The company’s revenue was up 3.8% compared to the same quarter last year.
Hedge funds and other institutional investors have recently modified their holdings of the business. Tibra Equities Europe Ltd acquired a new position in Gilead Sciences in the fourth quarter valued at approximately $2,239,000. Northern Trust Corp raised its stake in Gilead Sciences by 2.3% in the 4th quarter. Northern Trust Corp now owns 16,987,641 shares of the biopharmaceutical company’s stock valued at $1,062,577,000 after purchasing an additional 380,928 shares during the last quarter. Banco Santander S.A. raised its stake in Gilead Sciences by 19.1% in the 4th quarter. Banco Santander S.A. now owns 9,905 shares of the biopharmaceutical company’s stock valued at $619,000 after purchasing an additional 1,585 shares during the last quarter. Brookmont Capital Management raised its stake in Gilead Sciences by 1.2% in the 4th quarter. Brookmont Capital Management now owns 38,346 shares of the biopharmaceutical company’s stock valued at $2,399,000 after purchasing an additional 451 shares during the last quarter. Finally, CIBC Asset Management Inc grew its holdings in Gilead Sciences by 4.2% in the 4th quarter. CIBC Asset Management Inc now owns 316,734 shares of the biopharmaceutical company’s stock valued at $19,812,000 after buying an additional 12,698 shares in the last quarter. 78.69% of the stock is owned by hedge funds and other institutional investors.
In related news, Director John Francis Cogan sold 2,868 shares of the stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $64.89, for a total value of $186,104.52. Following the completion of the transaction, the director now directly owns 57,728 shares of the company’s stock, valued at approximately $3,745,969.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Brett A. Pletcher sold 5,816 shares of the stock in a transaction that occurred on Tuesday, June 18th. The stock was sold at an average price of $68.75, for a total value of $399,850.00. Following the completion of the transaction, the executive vice president now directly owns 27,198 shares of the company’s stock, valued at $1,869,862.50. The disclosure for this sale can be found here. Insiders sold a total of 11,384 shares of company stock valued at $755,002 over the last three months. Corporate insiders own 0.20% of the company’s stock.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 27th. Investors of record on Friday, June 14th were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 3.77%. The ex-dividend date was Thursday, June 13th. Gilead Sciences’s dividend payout ratio (DPR) is 40.98%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.